Please provide your email address to receive an email when new articles are posted on . Edwards Lifesciences announced it received FDA approval for its transcatheter valve with adaptive prestent for ...

WILMINGTON, DE / ACCESSWIRE / March 28, 2023 / Transparency Market Research Inc. - The pulmonary valve replacement market was valued at USD 1.0 Bn in 2022 and is projected to surpass USD 1.6 Bn by ...

Vancouver, Sept. 04, 2023 (GLOBE NEWSWIRE) -- The worldwide market for transcatheter pulmonary valve replacement reached a value of USD 44.62 Million in 2022. As per the most recent assessment ...

Please provide your email address to receive an email when new articles are posted on . Edwards Lifesciences Corporation announced that its transcatheter heart valve has received FDA approval for ...

Off-label use of the Sapien and Sapien XT valves represents a “viable and durable option” for restoring pulmonary valve function in patients with right-ventricular outflow tract (RVOT) disorders, ...

IRVINE, Calif., Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced U.S. Food and Drug ...

The FDA gave the greenlight to transcatheter pulmonic valve replacement with the Sapien 3 system plus an adaptive pre-stent landing zone, dubbed Alterra, for patients with congenital heart disease.

University of MIchigan Health C.S. Mott Children's Hospital, part of Ann Arbor-based Michigan Medicine, is among the first in the U.S. to perform a catheter-based pulmonary valve replacement on a ...

A major difficulty in the interpretation of these findings arises from the fact that closed commissurotomy often results in incomplete relief of obstruction, and it is difficult to determine whether ...